Definitive Healthcare (NASDAQ:DH) Issues Q1 2025 Earnings Guidance

Definitive Healthcare (NASDAQ:DH - Get Free Report) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.020-0.020 for the period, compared to the consensus earnings per share estimate of 0.070. The company issued revenue guidance of $55.5 million-$57.0 million, compared to the consensus revenue estimate of $60.0 million. Definitive Healthcare also updated its FY 2025 guidance to 0.190-0.220 EPS.

Definitive Healthcare Trading Down 12.4 %

Shares of Definitive Healthcare stock traded down $0.40 during trading on Monday, reaching $2.83. 1,413,851 shares of the stock were exchanged, compared to its average volume of 946,036. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm has a market cap of $326.93 million, a price-to-earnings ratio of -0.91, a price-to-earnings-growth ratio of 4.06 and a beta of 1.45. Definitive Healthcare has a 1 year low of $2.58 and a 1 year high of $9.11. The stock's fifty day moving average is $4.63 and its 200 day moving average is $4.48.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). The business had revenue of $62.29 million during the quarter, compared to analysts' expectations of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. As a group, equities research analysts expect that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have issued reports on DH shares. Barclays reduced their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a research report on Monday. Stephens assumed coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They set an "equal weight" rating and a $5.00 price target on the stock. Finally, Needham & Company LLC restated a "hold" rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Two analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Definitive Healthcare presently has an average rating of "Hold" and a consensus target price of $5.61.

Insiders Place Their Bets

In other news, insider William Moschella sold 45,000 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the sale, the insider now directly owns 433,830 shares of the company's stock, valued at approximately $2,039,001. This represents a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 14.84% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.